Company intelligence / Profile preview

Auxilart

Ownership: Private
Development stage: Other

Overview

Auxilart offers a mechanistic model-based digital simulation platform that accelerates pharmaceutical process development by replacing physical experiments with high-fidelity simulations. This approach reduces costs and time-to-market for pharma manufacturing optimization, reportedly cutting costs by up to 90% compared to traditional methods. The technology addresses the complexity of optimizing materials, methods, and equipment in drug manufacturing by enabling precise simulations with minimal data requirements.

No clinical results are reported as the company does not develop drugs directly.

Industry: Drug Discovery Services

Beyond the preview

Go deeper on Auxilart.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Auxilart.

Explore the full profile